Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $8 Million Underwritten Public Offering of BiondVax Pharmaceuticals Ltd.

Press Release – New York, NY – December 21, 2022 – Sichenzia Ross Ference LLP today announced that it represented Aegis Capital Corp. as sole book running manager in the $8 Million underwritten public offering of BiondVax Pharmaceuticals, a biotechnology company which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic products. The offering consisted of 1,600,000 units and pre-funded units, with each unit consisting of one American Depositary Share (“ADS”)  and two warrants, each to purchase one ADS,  at a combined purchase price of $5.00 per unit (or $4.999 per pre-funded unit after reducing $0.001 attributable to the exercise price of the pre-funded warrants).  The gross proceeds of the offering to the company were approximately $8 million.

The shares were issued pursuant to a Form F-1 registration statement (No. 333-267648) filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on December 15, 2022.  The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Darrin Ocasio, Barrett DiPaolo, and associates Matthew Siracusa and Mayank Pradhan.

• Author
• Recent Posts

Sichenzia Ross Ference Carmel LLP

SRFC is a full-service law firm with nationally recognized corporate, securities, and litigation practices that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRFC’s renowned litigation and regulatory department specializes in defending broker-dealers, registered persons, public and private corporations, and individuals in investigations and enforcement proceedings before the SEC, FINRA, and other regulatory bodies, as well as litigations and arbitrations across all forums in the securities industry, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations.

Latest posts by Sichenzia Ross Ference Carmel LLP (see all)

• Sichenzia Ross Ference Carmel LLP Represents Sharps Technology in $400 Million Private Placement - August 28, 2025
• 美国思成律师事务所代表Dominari Securities、Pacific Century Securities和Revere Securities完成Curanex Pharmaceuticals纳斯达克上市 - August 27, 2025
• Sichenzia Ross Ference Carmel LLP Represents Dominari Securities in $15 Million Initial Public Offering of Curanex Pharmaceuticals - August 27, 2025